<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02245087</url>
  </required_header>
  <id_info>
    <org_study_id>ECAD001</org_study_id>
    <nct_id>NCT02245087</nct_id>
  </id_info>
  <brief_title>Eliminate Coronary Artery Disease</brief_title>
  <acronym>ECAD</acronym>
  <official_title>Eliminate Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pharmacologic lowering of low density
      lipoprotein cholesterol (LDL), initiated in healthy young to middle aged adults can eliminate
      or markedly reduce the composite endpoint of incident all cause mortality, myocardial
      infarction, stroke or coronary revascularization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first occurrence of myocardial infarction, revascularization, stroke or death from any cause in the follow up period</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin(Lipitor) in addition to the usual guideline based care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guideline based care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Current guidelines for lipid-management in healthy middle aged men and women only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>20 mg of atorvastatin daily</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men 35-50 years of age

          -  Women 45 - 59 years of age (must be sterile or &gt;2 years postmenopausal)

          -  LDL cholesterol greater than 1.8 mmol/L (70 mg/dL) based on testing performed within 1
             year

          -  One risk factor for Coronary Heart Disease other than lipid abnormality:

          -  Obesity and hypertension [BP &gt;140 mmHg systolic and waist circumference &gt; 100 cm in
             men and &gt;90 cm in women]

          -  family history of premature myocardial infarction [&lt;60 years]

          -  South Asian ethnic history

          -  currently smoking

        Exclusion Criteria:

          -  Currently taking cholesterol lowering medication

          -  Qualify for cholesterol lowering medication based on current guidelines

          -  Significant renal dysfunction (creatinine clearance &lt;30 ml/min)

          -  Significant hepatic dysfunction (AST/ALT &gt;2.0 times upper limit of normal)

          -  Active malignancy

          -  Diabetes

          -  Progressive or terminal illness, or other condition in which subject is unlikely to
             survive the study period

          -  Known allergy, hypersensitivity (anaphylaxis) ar adverse reaction to any statin

          -  Participation in a clinical trial (except observational studies) within previous 30
             days

          -  Received any investigation product within 30 days prior to participation in this
             clinical trial

          -  Previously enrolled in this clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Michael Farkouh, MD, FRCPC, MSc, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter Munk Cardiac Centre, University Health Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J Domanski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter Munk Cardiac Centre, University Health Netowrk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Garrioch, BSc</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>2746</phone_ext>
    <email>amanda.garrioch@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Killian De Blacam Family Medical Practice</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3A 2A3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Garrioch, BSc</last_name>
      <email>amanda.garrioch@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Killian de Blacam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Gregory Garrioch Family Medical Practice</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 3C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Garrioch, BSc</last_name>
      <email>amanda.garrioch@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Gregory F Garrioch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Reena Dhatt</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E6C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reena Dhatt, MD FRCP CCFP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Michael Farkouh</investigator_full_name>
    <investigator_title>Chair of the Peter Munk Centre of Excellence in Multinational Clinical Trials, Peter Munk Cardiac Centre, UHN</investigator_title>
  </responsible_party>
  <keyword>atorvastatin</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>stroke</keyword>
  <keyword>revascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

